

Diana Karpman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1062802/publications.pdf>

Version: 2024-02-01

100
papers

6,567
citations

53794

45
h-index

64796

79
g-index

105
all docs

105
docs citations

105
times ranked

5736
citing authors

#	ARTICLE	IF	CITATIONS
1	Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. <i>Nature Reviews Immunology</i> , 2022, 22, 411-428.	22.7	61
2	IgG Binds Escherichia coli Serine Protease EspP and Protects Mice From E. coli O157:H7 Infection. <i>Frontiers in Immunology</i> , 2022, 13, 807959.	4.8	2
3	A role for complement blockade in kidney transplantation. , 2022, , .		2
4	A link between KrÄ¼ppel-like factor 4, complement activation, and kidney damage. <i>Kidney International</i> , 2022, 102, 14-16.	5.2	1
5	Isolation and Characterization of Shiga Toxin-Associated Microvesicles. <i>Methods in Molecular Biology</i> , 2021, 2291, 207-228.	0.9	1
6	Annexin Induces Cellular Uptake of Extracellular Vesicles and Delays Disease in Escherichia coli O157:H7 Infection. <i>Microorganisms</i> , 2021, 9, 1143.	3.6	10
7	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. <i>Frontiers in Immunology</i> , 2021, 12, 690821.	4.8	13
8	Extracellular vesicles in renal inflammatory and infectious diseases. <i>Free Radical Biology and Medicine</i> , 2021, 171, 42-54.	2.9	15
9	Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit. <i>Toxins</i> , 2020, 12, 449.	3.4	12
10	Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 212.	3.9	16
11	Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism. <i>Scientific Reports</i> , 2019, 9, 14362.	3.3	12
12	Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. <i>EBioMedicine</i> , 2019, 47, 319-328.	6.1	28
13	Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. <i>Pediatric Nephrology</i> , 2019, 34, 11-30.	1.7	230
14	Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. <i>Case Reports in Nephrology</i> , 2018, 2018, 1-4.	0.4	0
15	Aliskiren inhibits renin-mediated complement activation. <i>Kidney International</i> , 2018, 94, 689-700.	5.2	53
16	Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney. <i>EBioMedicine</i> , 2017, 16, 302-311.	6.1	2
17	Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis. <i>Kidney International</i> , 2017, 91, 96-105.	5.2	42
18	C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2472-2481.	6.1	30

#	ARTICLE	IF	CITATIONS
19	Extracellular vesicles in renal disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 545-562.	9.6	238
20	Orphan drug policies and use in pediatric nephrology. <i>Pediatric Nephrology</i> , 2017, 32, 1-6.	1.7	22
21	Haemolytic uraemic syndrome. <i>Journal of Internal Medicine</i> , 2017, 281, 123-148.	6.0	108
22	Microvesicle Involvement in Shiga Toxin-Associated Infection. <i>Toxins</i> , 2017, 9, 376.	3.4	29
23	Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic <i>Escherichia coli</i> Infected Mice. <i>Journal of Immunology</i> , 2016, 197, 1276-1286.	0.8	19
24	Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. <i>Kidney International</i> , 2016, 90, 726-729.	5.2	11
25	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. <i>Pediatric Nephrology</i> , 2016, 31, 15-39.	1.7	445
26	Shiga Toxin-Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cell-Derived Microvesicles in Hemolytic Uremic Syndrome. <i>Journal of Immunology</i> , 2015, 194, 2309-2318.	0.8	65
27	A Novel Mechanism of Bacterial Toxin Transfer within Host Blood Cell-Derived Microvesicles. <i>PLoS Pathogens</i> , 2015, 11, e1004619.	4.7	95
28	Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. <i>Advances in Experimental Medicine and Biology</i> , 2015, 865, 19-42.	1.6	48
29	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , 2014, 29, 1967-1978.	1.7	95
30	Eculizumab treatment for rescue of renal function in IgA nephropathy. <i>Pediatric Nephrology</i> , 2014, 29, 2225-2228.	1.7	101
31	The Combined Role of Galactose-Deficient IgA1 and Streptococcal IgA-Binding M Protein in Inducing IL-6 and C3 Secretion from Human Mesangial Cells: Implications for IgA Nephropathy. <i>Journal of Immunology</i> , 2014, 193, 317-326.	0.8	47
32	Enterohemorrhagic <i>Escherichia coli</i> Pathogenesis and the Host Response. <i>Microbiology Spectrum</i> , 2014, 2, .	3.0	42
33	Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy. <i>Journal of Immunology</i> , 2013, 191, 2184-2193.	0.8	59
34	Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. <i>Pediatric Nephrology</i> , 2013, 28, 155-158.	1.7	35
35	Ouabain Protects against Shiga Toxin-Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1413-1423.	6.1	37
36	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2899-2907.	0.7	25

#	ARTICLE	IF	CITATIONS
37	A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome. <i>Journal of Immunology</i> , 2012, 188, 2030-2037.	0.8	46
38	Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3669-3674.	0.7	17
39	The Antimicrobial Peptide Cathelicidin Protects Mice from Escherichia coli O157:H7-Mediated Disease. <i>PLoS ONE</i> , 2012, 7, e46476.	2.5	68
40	Phenotypic Expression of ADAMTS13 in Glomerular Endothelial Cells. <i>PLoS ONE</i> , 2011, 6, e21587.	2.5	19
41	Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. <i>Blood</i> , 2011, 117, 5503-5513.	1.4	163
42	Kinin system activation in vasculitis*. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2011, 100, 950-957.	1.5	2
43	Intestinal damage in enterohemorrhagic Escherichia coli infection. <i>Pediatric Nephrology</i> , 2011, 26, 2059-2071.	1.7	40
44	IgA nephropathy associated with a novel N-terminal mutation in factor H. <i>European Journal of Pediatrics</i> , 2011, 170, 107-110.	2.7	17
45	Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer. <i>Pediatric Blood and Cancer</i> , 2011, 56, 762-766.	1.5	25
46	Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3399-3403.	0.7	33
47	Cross-Reactive Protection against Enterohemorrhagic Escherichia coli Infection by Enteropathogenic E. coli in a Mouse Model. <i>Infection and Immunity</i> , 2011, 79, 2224-2233.	2.2	30
48	Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure. <i>Current Topics in Microbiology and Immunology</i> , 2011, 357, 105-136.	1.1	51
49	Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. <i>Pediatric Nephrology</i> , 2010, 25, 87-96.	1.7	34
50	Toll-Like Receptor 4 Promoter Polymorphisms: Common TLR4 Variants May Protect against Severe Urinary Tract Infection. <i>PLoS ONE</i> , 2010, 5, e10734.	2.5	90
51	Pathogen Specific, IRF3-Dependent Signaling and Innate Resistance to Human Kidney Infection. <i>PLoS Pathogens</i> , 2010, 6, e1001109.	4.7	68
52	Pathophysiology of Typical Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 575-585.	2.7	59
53	Antibody response to IgA-binding streptococcal M proteins in children with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3434-3436.	0.7	8
54	Tissue Deposits of IgA-Binding Streptococcal M Proteins in IgA Nephropathy and Henoch-Schönlein Purpura. <i>American Journal of Pathology</i> , 2010, 176, 608-618.	3.8	60

#	ARTICLE	IF	CITATIONS
55	Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin. <i>Journal of Immunology</i> , 2009, 182, 7906-7915.	0.8	50
56	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , 2009, 24, 687-696.	1.7	315
57	Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. <i>Pediatric Nephrology</i> , 2009, 24, 447-458.	1.7	17
58	Successful thrombolysis of neonatal bilateral renal vein thrombosis originating in the IVC. <i>Pediatric Nephrology</i> , 2009, 24, 2069-2071.	1.7	12
59	The contact/kinin and complement systems in vasculitis. <i>Apmis</i> , 2009, 117, 48-54.	2.0	10
60	A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2009, 46, 2236-2243.	2.2	39
61	Shiga Toxin and Lipopolysaccharide Induce Platelet-Leukocyte Aggregates and Tissue Factor Release, a Thrombotic Mechanism in Hemolytic Uremic Syndrome. <i>PLoS ONE</i> , 2009, 4, e6990.	2.5	113
62	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2008, 45, 95-105.	2.2	136
63	Shiga Toxin-Mediated Disease in MyD88-Deficient Mice Infected with <i>Escherichia coli</i> O157:H7. <i>American Journal of Pathology</i> , 2008, 173, 1428-1439.	3.8	41
64	Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. <i>Blood</i> , 2008, 111, 5307-5315.	1.4	128
65	Reduced Toll-Like Receptor 4 Expression in Children with Asymptomatic Bacteriuria. <i>Journal of Infectious Diseases</i> , 2007, 196, 475-484.	4.0	113
66	Inherited Susceptibility to Acute Pyelonephritis: A Family Study of Urinary Tract Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 1227-1234.	4.0	86
67	Factor H dysfunction contributes to platelet activation in hemolytic uremic syndrome (HUS). <i>Molecular Immunology</i> , 2007, 44, 191-192.	2.2	0
68	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. <i>Molecular Immunology</i> , 2007, 44, 1835-1844.	2.2	73
69	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2007, 44, 3971.	2.2	0
70	A Genetic Basis of Susceptibility to Acute Pyelonephritis. <i>PLoS ONE</i> , 2007, 2, e825.	2.5	85
71	Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2007, 138, 651-662.	2.5	84
72	Anguish over angiopathy: Hemolytic uremic syndrome. <i>Clinical Immunology</i> , 2007, 122, 135-138.	3.2	0

#	ARTICLE	IF	CITATIONS
73	ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. <i>European Journal of Pediatrics</i> , 2007, 166, 249-257.	2.7	25
74	Uropathogenic <i>Escherichia coli</i> as a model of host-parasite interaction. <i>Current Opinion in Microbiology</i> , 2006, 9, 33-39.	5.1	98
75	A common origin of the 4143insA ADAMTS13 mutation. <i>Thrombosis and Haemostasis</i> , 2006, 96, 3-6.	3.4	74
76	Lipopolysaccharide from enterohemorrhagic <i>Escherichia coli</i> binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. <i>Blood</i> , 2006, 108, 167-176.	1.4	166
77	Platelet Activation in Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 128-145.	2.7	47
78	Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 113-120.	2.7	91
79	Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. <i>Kidney International</i> , 2003, 63, 1995-1999.	5.2	83
80	Contact-system activation in children with vasculitis. <i>Lancet, The</i> , 2002, 360, 535-541.	13.7	35
81	Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. <i>Current Paediatrics</i> , 2002, 12, 569-574.	0.2	14
82	Antibodies to intimin and <i>Escherichia coli</i> secreted proteins A and B in patients with enterohemorrhagic <i>Escherichia coli</i> infections. <i>Pediatric Nephrology</i> , 2002, 17, 201-211.	1.7	35
83	Human renal epithelial cells express iNOS in response to cytokines but not bacteria. <i>Kidney International</i> , 2002, 61, 444-455.	5.2	24
84	Correct evaluation of renal glomerular filtration rate requires clearance assays. <i>Pediatric Nephrology</i> , 2002, 17, 847-851.	1.7	33
85	Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. <i>Blood</i> , 2001, 97, 3100-3108.	1.4	127
86	Fimbriae, Transmembrane Signaling, and Cell Activation. <i>Journal of Infectious Diseases</i> , 2001, 183, S47-S50.	4.0	36
87	Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome. <i>Pediatric Research</i> , 2001, 50, 163-171.	2.3	180
88	Interleukin-8 Receptor Deficiency Confers Susceptibility to Acute Pyelonephritis. <i>Journal of Infectious Diseases</i> , 2001, 183, S56-S60.	4.0	63
89	The λ -innate host response protects and damages the infected urinary tract. <i>Annals of Medicine</i> , 2001, 33, 563-570.	3.8	41
90	Interleukin 8 Receptor Deficiency Confers Susceptibility to Acute Experimental Pyelonephritis and May Have a Human Counterpart. <i>Journal of Experimental Medicine</i> , 2000, 192, 881-890.	8.5	175

#	ARTICLE	IF	CITATIONS
91	Innate Defences and Resistance to Gram Negative Mucosal Infection. , 2000, 485, 9-24.		11
92	Multimeric Î±-Lactalbumin from Human Milk Induces Apoptosis through a Direct Effect on Cell Nuclei. Experimental Cell Research, 1999, 246, 451-460.	2.6	96
93	CYTOKINE REPERTOIRE OF EPITHELIAL CELLS LINING THE HUMAN URINARY TRACT. Journal of Urology, 1998, 159, 2185-2192.	0.4	60
94	CYTOKINE REPERTOIRE OF EPITHELIAL CELLS LINING THE HUMAN URINARY TRACT. Journal of Urology, 1998, , 2185-2192.	0.4	2
95	Apoptosis of Renal Cortical Cells in the Hemolytic-Uremic Syndrome: In Vivo and In Vitro Studies. Infection and Immunity, 1998, 66, 636-644.	2.2	161
96	Bernardâ€™s Soulier syndrome Karlstad: Trp 498â€™Stop mutation resulting in a truncated glycoprotein IbÎ± that contains part of the transmembranous domain. British Journal of Haematology, 1997, 98, 57-63.	2.5	28
97	von Willebrand Factor Mediates Increased Platelet Retention in Recurrent Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 1997, 78, 1456-1462.	3.4	19
98	Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. Kidney International, 1996, 49, 190-199.	5.2	25
99	Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatric Nephrology, 1995, 9, 694-699.	1.7	124
100	Enterohemorrhagic Escherichia coli Pathogenesis and the Host Response. , 0, , 381-402.		1